巴曲酶联合神经节苷脂治疗急性脑梗死的临床疗效观察
|
摘要
目的探讨巴曲酶联合神经节苷脂治疗急性脑梗死的临床疗效。方法选取2017年1月～2018年6月于我院就诊的急性脑梗死患者100例作为研究对象,两组患者均予脱水、降压、降脂、降糖、抗凝及抗自由基等常规治疗,观察组同时联合巴曲酶和神经节苷脂治疗,两组均连续治疗14 d,治疗后对比分析两组的临床疗效、治疗前后NIHSS评分的变化情况。结果观察组与对照组的基本治愈率分别为40.0%、38.0%,两组比较,差异不显著(P>0.05)。观察组与对照组患者治疗后的总有效率分别为96.0%、76.0%,两组疗效对比,差异存在显著性(P<0.05)。观察组患者治疗1周后的NIHSS评分为(14.82±5.28)分、治疗2周后的NIHSS评分为(7.97±1.39)分,均显著低于治疗前,差异具有统计学意义(P<0.05)。结论巴曲酶联合神经节苷脂治疗急性脑梗死可以显著提高临床疗效,从而发挥保护脑细胞、促进神经功能恢复的作用。
Objective To explore the clinical efficacy of batroxobin combined with ganglioside in the treatment of acute cerebral infarction. Methods A total of 100 patients with acute cerebral infarction who were treated in our hospital from January 2017 to June 2018 were selected as subjects. Both groups were treated with conventional treatments such as dehydration, hypotension, lipid lowering, hypoglycemic, anticoagulant and anti-free radicals. The observation group was combined with batroxobin and ganglioside treatment. The two groups were treated continuously for 14 days. After treatment, the clinical efficacy and the changes of NIHSS scores before and after treatment were compared. Results The basic cure rates of the observation group and the control group were 40.0% and 38.0%, respectively, and the difference between the two groups was not significant(P>0.05). The total effective rate of the observation group and the control group after treatment was 96.0% and 76.0%, respectively, showing significant difference between the two groups(P<0.05). The NIHSS score of the observation group was(14.82±5.28) points after 1 week of treatment, and(7.97±1.39) points after 2 weeks of treatment, which were significantly lower than those before treatment, and the differences were statistically significant(P<0.05). Conclusion Batroxobin combined with ganglioside in the treatment of acute cerebral infarction can significantly improve the clinical efficacy, thereby playing a role in protecting brain cells and promoting the recovery of nerve function.
Objective To explore the clinical efficacy of batroxobin combined with ganglioside in the treatment of acute cerebral infarction. Methods A total of 100 patients with acute cerebral infarction who were treated in our hospital from January 2017 to June 2018 were selected as subjects. Both groups were treated with conventional treatments such as dehydration, hypotension, lipid lowering, hypoglycemic, anticoagulant and anti-free radicals. The observation group was combined with batroxobin and ganglioside treatment. The two groups were treated continuously for 14 days. After treatment, the clinical efficacy and the changes of NIHSS scores before and after treatment were compared. Results The basic cure rates of the observation group and the control group were 40.0% and 38.0%, respectively, and the difference between the two groups was not significant(P>0.05). The total effective rate of the observation group and the control group after treatment was 96.0% and 76.0%, respectively, showing significant difference between the two groups(P<0.05). The NIHSS score of the observation group was(14.82±5.28) points after 1 week of treatment, and(7.97±1.39) points after 2 weeks of treatment, which were significantly lower than those before treatment, and the differences were statistically significant(P<0.05). Conclusion Batroxobin combined with ganglioside in the treatment of acute cerebral infarction can significantly improve the clinical efficacy, thereby playing a role in protecting brain cells and promoting the recovery of nerve function.
引文
[1]韩春娜.巴曲酶治疗脑梗死65例临床疗效观察[J].中国当代医药,2010,17(2):65-66.
[2]俞斌.巴曲酶联合长春西汀治疗急性脑梗死34例[J]中国药业,2013,22(1):52-53.
[3]罗建宁.急性脑梗死治疗新进展[J].实用心脑肺血管病杂志,2010,18(10):1546-1547.
[4]陈江波,刘新生,李时光.巴曲酶联合丁苯酞治疗急性脑梗死的疗效观察[J].中国实用神经疾病杂志,2012,15(6):32-33.
[5]莫俊宁,李又佳,黄燕.尤瑞克林联合巴曲酶治疗急性脑梗死的疗效观察[J].中国基层医药,2015,22(2):178-179.
[6]赵玉娟.依达拉奉联合神经节苷脂对脑梗死患者神经功能缺损症状和生活能力的影响[J].重庆医学,2015,44(9):1226-1227.
[7]熊云彪,周飞鹏,杨承勇,等.神经节苷脂对急性颅脑损伤患者的脑保护作用[J].中华创伤杂志,2012,28(8):685-686.
[8]王立珍.神经节苷脂治疗新生儿缺氧缺血性脑病的临床疗效观察[J].中西医结合研究,2012,4(1):33-34.
[9]邹利添,古金花,陈国新,等.依达拉奉联合神经节苷脂治疗急性脑梗死疗效观察[J].中国实用神经疾病杂志,2011,14(11):45-47.
[10]粱慧.巴曲酶治疗急性脑梗死疗效观察[J].中国民康医学,2013,25(12):31-32.
[11]崔建丰.巴曲酶治疗急性脑梗死的疗效观察[J].当代医学,2014,20(19):142-143.
[12]孟燕.巴曲酶治疗急性脑梗死60例疗效观察[J].山东医药,2011,51(5):106-107.
[13]胡昌盛,左佳丽,周良斌.巴曲酶、单唾液酸四己糖神经节苷脂治疗急性脑梗死的疗效观察[J].实用心脑肺血管病杂志,2011,19(8):1297-1298.
[14]邢付强.巴曲酶联合神经节苷脂治疗急性脑梗死疗效观察[J].现代预防医学,2012,39(2):520-521.
[15]杨铭.巴曲酶联合神经节苷脂治疗急性脑梗死的临床疗效分析[J].中国医药,2013,8(7):927-928.
[16]黄友发,孙平,杨言府.巴曲酶治疗进展性脑梗死45例临床观察[J].中国实用神经疾病杂志,2010,13(10):77-78.
[17]施列鸿.巴曲酶联合神经节苷脂治疗急性脑梗死的临床研究[J].检验医学与临床,2014,11(24):3476-3477.
[2]俞斌.巴曲酶联合长春西汀治疗急性脑梗死34例[J]中国药业,2013,22(1):52-53.
[3]罗建宁.急性脑梗死治疗新进展[J].实用心脑肺血管病杂志,2010,18(10):1546-1547.
[4]陈江波,刘新生,李时光.巴曲酶联合丁苯酞治疗急性脑梗死的疗效观察[J].中国实用神经疾病杂志,2012,15(6):32-33.
[5]莫俊宁,李又佳,黄燕.尤瑞克林联合巴曲酶治疗急性脑梗死的疗效观察[J].中国基层医药,2015,22(2):178-179.
[6]赵玉娟.依达拉奉联合神经节苷脂对脑梗死患者神经功能缺损症状和生活能力的影响[J].重庆医学,2015,44(9):1226-1227.
[7]熊云彪,周飞鹏,杨承勇,等.神经节苷脂对急性颅脑损伤患者的脑保护作用[J].中华创伤杂志,2012,28(8):685-686.
[8]王立珍.神经节苷脂治疗新生儿缺氧缺血性脑病的临床疗效观察[J].中西医结合研究,2012,4(1):33-34.
[9]邹利添,古金花,陈国新,等.依达拉奉联合神经节苷脂治疗急性脑梗死疗效观察[J].中国实用神经疾病杂志,2011,14(11):45-47.
[10]粱慧.巴曲酶治疗急性脑梗死疗效观察[J].中国民康医学,2013,25(12):31-32.
[11]崔建丰.巴曲酶治疗急性脑梗死的疗效观察[J].当代医学,2014,20(19):142-143.
[12]孟燕.巴曲酶治疗急性脑梗死60例疗效观察[J].山东医药,2011,51(5):106-107.
[13]胡昌盛,左佳丽,周良斌.巴曲酶、单唾液酸四己糖神经节苷脂治疗急性脑梗死的疗效观察[J].实用心脑肺血管病杂志,2011,19(8):1297-1298.
[14]邢付强.巴曲酶联合神经节苷脂治疗急性脑梗死疗效观察[J].现代预防医学,2012,39(2):520-521.
[15]杨铭.巴曲酶联合神经节苷脂治疗急性脑梗死的临床疗效分析[J].中国医药,2013,8(7):927-928.
[16]黄友发,孙平,杨言府.巴曲酶治疗进展性脑梗死45例临床观察[J].中国实用神经疾病杂志,2010,13(10):77-78.
[17]施列鸿.巴曲酶联合神经节苷脂治疗急性脑梗死的临床研究[J].检验医学与临床,2014,11(24):3476-3477.